Celularity To Present Data Showing Senescent Cell Elimination By Off-The-Shelf Natural Killer Cells Derived From Human Placental Cells
Celularity To Present Data Showing Senescent Cell Elimination By Off-The-Shelf Natural Killer Cells Derived From Human Placental Cells
Celularity Inc. (NASDAQ:CELU) ("Celularity"), a biotechnology company developing placental-derived allogeneic cell therapies and advanced biomaterial products, announced today that it will present in vitro data from its investigational natural killer (NK) cell therapy programs at this year's American Society of Gene and Cell Therapy (ASGCT) Annual Meeting. The preclinical data, which suggest that Celularity's placenta-derived unmodified natural killer (NK) cells (CYNK-001) and genetically modified NK cells (CYNK-201) may serve as potent and selective senolytic agents for use in addressing age-related diseases, will be presented on May 9, 2024.
開發胎盤衍生異基因細胞療法和先進生物材料產品的生物技術公司Celularity Inc.（納斯達克股票代碼：CelU）（“Celularity”）今天宣佈，將在今年的美國基因與細胞療法學會（ASGCT）年會上公佈其研究性自然殺傷（NK）細胞療法項目的體外數據。臨床前數據將於2024年5月9日發佈，這些數據表明，Celularity的胎盤衍生未經改良的自然殺傷（NK）細胞（CYNK-001）和轉基因NK細胞（CYNK-201）可以作爲強效的選擇性溶解劑，用於治療與年齡相關的疾病。
Senescent cells are key drivers in the process of age-related cellular corruption at the heart of degenerative diseases, cancer and immuno-senescence (the progressive decline in immune function that occurs with age). These cells are unique in that they eventually stop multiplying but do not die; instead, they transform into the senescence associated secretory phenotype (SASP) and continue to release chemicals that can promote inflammation and tumor progression. Moreover, if not eliminated, these cells impair the normal regenerative process that restores function to organs and tissues.
衰老細胞是退行性疾病、癌症和免疫衰老（免疫功能隨着年齡的增長而逐漸下降）的核心，衰老細胞是與年齡相關的細胞腐蝕過程的關鍵驅動因素。這些細胞的獨特之處在於它們最終停止繁殖但不會死亡；相反，它們轉化爲衰老相關分泌表型（SASP），並繼續釋放可促進炎症和腫瘤進展的化學物質。此外，如果不消除，這些細胞會損害恢復器官和組織功能的正常再生過程。
Celularity is building a broad technology platform that leverages the placenta's unique immunobiology as a source of highly expandable, off-the-shelf cells, as well as a diverse portfolio of cell therapy investigational products to address age-related diseases, including cancer and degenerative diseases. Celularity believes these preclinical data demonstrate the potential of its assets to target and selectively remove damaged and abnormal cells expressing stress ligands, such as senescent, virally infected and cancer cells.
Celularity正在建立一個廣泛的技術平台，該平台利用胎盤獨特的免疫生物學作爲高度可擴展的現成細胞的來源，以及多樣化的細胞療法研究產品組合，以解決與年齡相關的疾病，包括癌症和退行性疾病。Celularity認爲，這些臨床前數據表明，其資產有可能靶向和選擇性地去除表達壓力配體的受損和異常細胞，例如衰老細胞、病毒感染細胞和癌細胞。
"Celularity believes in the broad, but so far underrealized, potential of cell therapies. We continue to investigate cellular immunotherapy in age-related diseases, and these data are an important, continued step in demonstrating how our therapeutic assets may be used to eliminate senescent cells," said Celularity's CEO and Founder Dr. Robert Hariri, M.D., Ph.D. "Removing these aging, senescent cells, which we have termed 'senoablation,' may represent an important clinical approach to address the high societal cost of age-associated diseases and disabilities."
“Celularity相信細胞療法具有廣泛但迄今尚未實現的潛力。我們將繼續研究年齡相關疾病的細胞免疫療法，這些數據是證明我們的治療資產如何用於消滅衰老細胞的重要而持續的一步，” Celularity首席執行官兼創始人羅伯特·哈里里博士說，“去除這些衰老的衰老細胞，我們稱之爲'去除'，可能是解決年齡相關疾病高昂社會成本的重要臨床方法和殘疾。”
The ASGCT Annual Meeting will take place on May 7 through 11, 2024, in Baltimore, Md.
ASGCT年會將於2024年5月7日至11日在馬里蘭州巴爾的摩舉行。
譯文內容由第三人軟體翻譯。